|
|
Join a Clinical Trial
The Society for Women’s Health Research (SWHR) was founded to bring national attention to the problem of the exclusion of women from medical research and clinical trials and the need for greater federal funding for diseases and conditions prevalent in, and unique to women. Historically women had been left out of medical research studies because doctors and scientists did not believe there were important differences in how diseases affected men and women. These
differences are now recognized as key factors in understanding how our bodies work and fight disease.
To help women find clinical trials in which they might like to participate, SWHR has begun to list trials that are recruiting women for various conditions. SWHR does not endorse or recommend any trial and is only providing the information as a service. Choosing to take part in a medical research study is a decision that you make with the help of family, friends, health care professionals, and others you trust and respect. Below you will find lists of clinical trials that need participants, the condition the trial is studying, who qualifies, and contact information for the research coordinators and investigators. Additional information
about these trials and other clinical trials can be found at www.clinicaltrials.gov and www.womancando.org
Although we know more today and often take health advances for granted, much remains to be learned. Whether you have a disease or condition that needs treatment or are in perfect health, you can play an important role in improving health care. By volunteering to take part in a research study, you can make a valuable contribution to medical knowledge for your own health and the health of all future generations of women.
Need more information? Visit our Clinical Trials FAQ page.
Click to jump to a specific topic:
Alzheimer's Disease Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
ADNI GO is a landmark research study sponsored by the National Institute on Aging (NIA) at the National Institutes of Health (NIH). It is examining the sequence and timing of events at the initial onset of mild cognitive symptoms and may help scientists to better identify who is at risk for AD, as well as the effectiveness of potential prevention and treatment strategies. This two-year, $24 million study focuses for the first time on people experiencing the very earliest complaints of memory problems that affect their daily activities. ADNI GO expands on the groundbreaking Alzheimer’s Disease Neuroimaging Initiative (ADNI), the largest and most comprehensive study of its kind to date, and will continue efforts to identify biomarkers that can help build a greater understanding of the progression of AD. |
Please contact the research site in your area to see if you qualify. For a list of sites please visit the ADNI GO Study's website. |
Please visit the ADNI GO Study's website for a list of participating Clinical Study Research sites and their contact information. |
Back to Top
Breast Cancer Studies:
www.BreastCancerTrials.org (BCT.org) is a free, nonprofit, clinical trial matching service that can help you quickly and easily find breast cancer trials that might be right for you. BCT.org has easy-to-read trial summaries and a secure message service for contacting participating research sites. You also can sign up for their trial alert service to learn about newly added trials that match your health history.
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
| The XPAND Study. Evaluation of a needle free, patient controlled tissue expander. The goal of the XPAND study is to compare the AeroForm patient controlled tissue expander to traditional saline expanders used in breast reconstruction surgery. Measurements will include time to expansion and permanent implant exchange, pain and ease of use. |
Participants must be women 18-65 years old, requiring tissue expansion for breast reconstruction. Written consent will be required as will compliance with the study requirements. Participants cannot be smokers, have had prior surgery or radiation at the intended expansion site, are pregnant or have currently implanted electronic devices. |
Please visit clinicaltrials.gov (NCT01425268) for a list of participating sites and the corresponding study coordinator's contact information. |
Back to Top
Breast Imaging Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool. The goal of this study is to determine if a new technology using specialized gamma cameras can detect cancers in dense breast tissue better than mammography. |
Participants must be women, 40 years old or older, have dense breasts on mammography and additional risk factors for breast cancer. |
mbi@mayo.edu |
|
Evaluation of Molecular Breast Imaging in the Detection of Breast Cancer in Patients with High Risk Benign Breast Lesions. The goal of this study is to determine if a new technology using specialized gamma cameras can detect cancer in women who have been diagnosed with lesions
which indicate an increased risk of developing breast cancer. |
Participants must be women, 18 years old or older, either with recently diagnosed or history of high risk lesions of the breast, including atypia, radial scar, or lobular carcinoma in situ. |
mbi@mayo.edu
|
|
Study of Molecular Breast Imaging in Women Initiating or Discontinuing Hormone Therapy. This study evaluates if a new technology using specialized gamma cameras can detect changes in breast tissue due to use of hormone therapy. |
Participants must be women who are scheduled to begin or stop using either 1) estrogen or 2) combination estrogen/progesterone therapy in the form of a pill or patch. |
mbi@mayo.edu
|
Back to Top
Contraception Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
| The NEW CHOICE STUDY is a 12-month, nationwide clinical study involving 1,500 women of reproductive age who are looking for birth control. This study will assess the safety and efficacy of a contraceptive option for women. The option being studied is a once-weekly, low-dose investigational contraceptive patch that has been developed to prevent pregnancy. |
To know if you are eligible, answer 8 simple questions on the Eligibility page of: www.newchoicestudy.com.
You must be 18-40 years of age, sexually active and looking for birth control, generally in good health. If you smoke, you must be under 35 years of age. See website for additional information.
|
To learn more about the study, see if you are eligible, and locate a Study Center near you, go to www.newchoicestudy.com. |
| Oral Contraceptives for the Prevention of Pregnancy in Normal Sexually Active Women who are at Risk for Pregnancy.
|
Participants must be sexually active women, 18-40 years old, who have a history of regular menstrual cycles.
|
Carol Mack at cmack@jamesasimonmd.com or 202-293-1000
|
| Oral Contraceptives for the Prevention of Menstrually-Related Migraine Headaches.
|
Participants must be women aged 18-35 years old who have a history of regular menstrual cycles and of migraines associated with their cycles. Participants must be non-smokers.
|
Pat DeHof at pdehof@jamesasimonmd.com or 202-293-1000
|
| Oral Contraceptive Use in Adolescents(12-18y): Impact on Peak Bone Density.
|
Participants must be young women, 12-18 years old and have a history of regular menstrual cycles (this study includes a control group which would not require the participant to take oral contraception).
|
Pat DeHof at pdehof@jamesasimonmd.com or 202-293-1000
|
| An open label study of combined oral contraceptive. The goal of this study is to test a new formulation and regimen for two already FDA approved active ingredients for prevention of pregnancy.
|
Participants must be 18-35 years of age, who have a history of regular menstrual cycles.
|
Holly Spalt at hspalt@jamesasimonmd.com or 202-293-1000
|
Back to Top
Decreased Sexual Desire Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
National Registry of Women with Decreased Sexual Desire (known as Hypoactive Sexual Desire Disorder or HSDD). This study involves no study related treatment or medication.
|
Participants must be women, 18 years old or older and experiencing decreased sexual desire.
|
Pat DeHof at pdehof@jamesasimonmd.com or 202-293-1000
|
|
A Novel Non-hormonal Therapy for Decreased Sexual Desire (known as Hypoactive Sexual Desire Disorder or HSDD) in Premenopausal Women.
|
Participants must be premenopausal women, 18 years old or older and experiencing decreased sexual
desire.
|
Carol Mack at cmack@jamesasimonmd.com or 202-293-1000
|
|
A Novel Non-hormonal Therapy for Decreased Sexual Desire (known as Hypoactive Sexual Desire Disorder or HSDD) in Postmenopausal Women.
|
Participants must be postmenopausal women experiencing decreased sexual desire.
|
Pat DeHof at pdehof@jamesasimonmd.com or 202-293-1000
|
|
Testosterone Gel Therapy in the Treatment of Decreased Sexual Desire (known as Hypoactive Sexual Desire Disorder or HSDD) in Postmenopausal Women after Hysterectomy with Removal of the Ovaries.
|
Participants must be surgically postmenopausal women experiencing decreased sexual desire.
|
Carol Mack at cmack@jamesasimonmd.com or 202-293-1000
|
| Testosterone Gel in the Treatment of Decreased Sexual Desire (known as Hypoactive Sexual Desire Disorder or HSDD) in Postmenopausal Women with Cardiac Risk Factors (high blood pressure, elevated cholesterol, etc.
|
Participants must be postmenopausal women who have at least one cardiac risk factor, such as high blood pressure or elevated cholesterol.
|
Carol Mack at cmack@jamesasimonmd.com or 202-293-1000
|
| Premenopausal women with low sexual desire or arousal disorder. A new non-hormonal therapy for both sexual desire and arousal will be tested during this study.
|
Premenopausal women with low sexual desire or difficulty becoming sexually aroused.
|
Holly Spalt at hspalt@jamesasimonmd.com or 202-293-1000
|
Back to Top
Diet and Weight Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
Effects of study medication for weight loss in men and women. Testing an FDA approved drug for the purpose of weight loss in obese individuals. Dietary counseling is included for all participants. |
Obese women and men who are committed to losing weight. |
Carol Mack at cmack@jamesasimonmd.com 202-293-1000 |
Back to Top
Heart Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
CABANA - Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation
This is a comparative randomized clinical trial for the treatment of Atrial Fibrillation. The intent of the CABANA trial is to enroll patients who have new onset or under-treated paroxysmal, persistent, or longstanding persistent atrial fibrillation and who warrant therapy for their arrhythmia.
|
Key Inclusion criteria
- >18 years of age.
- ECG-documented AF episodes >1 hour in duration.
- Eligible for catheter ablation and >2 sequential rhythm control and/or >3 rate control drugs.
- >65 yrs of age, or <65 yrs with at least one stroke risk factor: Hypertension, diabetes mellitus, prior stroke or TIA, congestive heart failure or LVEF <35%, or left atrial enlargement (> 5.0 cm).
Key Exclusion Criteria
- Lone AF in patients <65 years of age
- Patients who have failed >2 anti-arrhythmic drugs at a therapeutic dose due to inefficacy or side effects
- More than one week of amiodarone treatment in the past 3 months
- An efficacy failure of full dose amiodarone treatment >12 weeks duration at any time
- Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent major surgical procedures, or trauma
- Prior LA catheter ablation with the intention of treating AF
- Contraindication to warfarin anti-coagulation
The Arrhythmia Service at Johns Hopkins Medicine is currently recruiting for this trial under the direction of Dr. Hugh Calkins and Dr. Joseph Marine.
|
If your physician has determined that you have an abnormal heart rhythm called atrial fibrillation that requires treatment, please contact the Johns Hopkins Research Coordinator at erobin26@jhmi.edu for study information.
Visit the trial website. The study is registered on the clinical trials website.
|
Back to Top
IBS Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
| A Placebo-Controlled Trial of Lyrica for Irritable Bowel Syndrome (IBS). This
study involves one study visit, taking study drug or placebo for 12 weeks, and completion of a questionnaire at home every week for 12 weeks. |
Women and men over the age of 18-70 who have been diagnosed with irritable bowel syndrome (IBS). |
Annie Almazar at almazarelder.ann@mayo.edu or 507-284-5010 |
Back to Top
Incontinence Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
| Randomized trial comparing Burch and mid-urethral slings (two surgical procedures to treat urinary incontinence related to coughing, laughing or physical activities) performed with sacral colpopexy (a surgical procedure to correct vaginal prolapse. Also called
cystocele, rectocele, uterine prolapse or enterocele). |
Participants must be women, older than 18, have completed childbearing, and have symptomatic pelvic organ prolapse (protrusion of the vagina through the vaginal opening) and urinary incontinence. |
Amy Reynolds at
reynolds.amy@mayo.edu or 507-293-0018 |
| Controlled study of the use of clonidine to help symptoms of urge fecal incontinence in women. Anorectal assessments and a pelvic MR done at no expense. Remuneration offered.
|
Participants must be women, between 18-75 years old, and experiencing involuntary stool leakage not associated with other rectal disorders (rectal cancer, inflammatory bowel disease, etc.). |
Jessica Edge at edge.jessica@mayo.edu or 507-255-6802 |
Back to Top
Menopausal Symptom Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
Vaginal DHEA (a naturally occurring pre-hormone) in the Treatment of Postmenopausal Vulvar/Vaginal Atrophy
|
Participants must be postmenopausal women ages 40-75 years old who are experiencing moderate to severe pain at intercourse.
|
Carol Mack at cmack@jamesasimonmd.com or 202-293-1000
|
|
An Oral SERM (a non-estrogenic drug which acts like an estrogen or anti-estrogen depending upon the tissue [SERM]) for the Treatment of Moderate to Severe Postmenopausal Hot Flashes (VMS)
|
Participants must be postmenopausal women who are experiencing sever hot flashes. If naturally postmenopausal, participant must be 45-60 years old. If surgically postmenopausal, participant must be 35-60 years old).
|
Pat DeHof at pdehof@jamesasimonmd.com or 202-293-1000
|
Back to Top
Pain Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
Constipation from Prescription Opioid Pain Medicines:
If you regularly take a prescription opioid pain medicine, such as morphine, and also experience constipation, you may be eligible to participate in a clinical research study. AstraZeneca is sponsoring a clinical research study to determine whether an investigational drug is safe and effective to treat constipation as a side effect in people taking opioid pain medicines. The study may last up to 18 weeks with an option to continue in the long-term safety study.
|
Participants must be:
- 18 or older and live in the United States;
-
Taking at least one prescription opioid pain medicine, every day for at least four weeks; and
-
Also experiencing constipation
|
For more information and to find out if you are eligible, please visit www.theKODIACstudy.com or call 1-866-320-6957
|
Back to Top
Sexual Health Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
A Randomized, Double-Blind, Placebo-Controlled Research Study to Evaluate a
Novel Vulvar Cream Containing Cutaneous Lysate for Provoked Vestibulodynia
Seeking Women in AZ, CA, DC, PA, & NY
|
Women between the ages of 20 and 55 who are not pregnant or breastfeeding may be eligible to participate in this study. Women must experience pain with tampon insertion and/or intercourse that affects their sexual function, and practice a reliable form of birth control. Those with a history of diabetes, heart disease, HIV, hepatitis B or C, or menopause are not eligible. Women must be able to attend two clinic visits, plus two telephone interviews, and complete all questionnaires in English over the course of the 12-week study. The study cream and other related study tests will be provided at no cost. |
Participating Centers:
The Centers for Vulvovaginal Disorders (Washington, DC)
Contact Hillary Tolson
202-887-0568
Principal Investigator: Andrew T. Goldstein, MD
Pelvic & Sexual Health Institute (Philadelphia, PA)
Contact Elizabeth Elias, CCRC
215-863-8100
Principal Investigator: Kristene Whitmore, MD
Co-Investigator: Susan Kellogg-Spadt, PhD, PA-C
San Diego Sexual Medicine (San Diego, CA)
Contact Margaret Carr
619-265-7691, information@sdsm.info
Principal Investigator: Irwin Goldstein, MD
Arizona Vulva Clinic (Phoenix, AZ)
Contact Gabrielle Rodriguez
602-265-1112
Principal Investigator: Joseph Brooks, MD
New York Center for Women's Health Research (New York, NY)
Contact Lauren Pellegrino, WHNP-BE
649-290-9560
Principal Investigator: Kenneth A. Levey, MD
|
|
Queen's Sexual Health Research Lab - The purpose of this study is to help determine the causes of and possible treatments for women's pain during intercourse.
There are several in-lab studies examining:
- 2 non-medical treatments for genital pain
- Genital pain sensitivity
- Genital blood flow
- Pain processing with brain imaging
- Pelvic floor muscles with ultrasound imaging
- Verbal interactions between couples
There are also several online studies for women with or without the above criteria.
|
Participants must be:
-
Females
- 18 years or older
- Experience pain during intercourse or have pain such as migraine headaches that cause arousal difficulties
|
For more information, please contact the Sexual Health Research Lab at SHRL@queensu.ca or 613-533-3276 |
|
A vaginal estrogen for postmenopausal women with vaginal dryness, pain during sexual intercourse or vaginal atrophy. A new formulation of a naturally occurring estradiol gel will be tested.
|
Participants must be postmenopausal with vaginal dryness, and pain with sexual activity not adequately relieved by lubricants and/or moisturizers.
|
Holly Spalt at hspalt@jamesasimonmd.com or 202-293-1000 |
Back to Top
Spina Bifida Studies:
|
The Studies
|
Who Qualifies
|
The Research Coordinators
|
|
MOMS: Management of Myelomeningocele Study - to understand which treatment - postnatal or prenatal surgery - is more effective in treating those with the condition. Read More |
Participants must be 18 years and older. They must be pregnant women carrying a fetus diagnosed with myelomeningocele. See More |
Study Coordinator at moms@biostat.bsc.gwu.edu or 1-866-275-6667 |
Back to Top
More Trials
|
